BCRX insider transaction filings
BIOCRYST PHARMACEUTICALS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-15. Screen BCRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | McKee Amy E — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | HEGGIE THERESA — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | SANDERS MACHELLE — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Milne Jill C. — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Frank Steven — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Galson Steven K — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Stonehouse Jon P — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | MILANO VINCENT — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | LEVIN ALAN G — Director | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | McKee Amy E — Director | Grant/award (A): 631 @ $8.91 | EDGAR |
| 2026-06-02 | 4 | Milne Jill C. — Director | Grant/award (A): 1,262 @ $8.91 | EDGAR |
| 2026-06-02 | 4 | Frank Steven — Director | Grant/award (A): 1,262 @ $8.91 | EDGAR |
| 2026-06-02 | 4 | Stonehouse Jon P — Director | Grant/award (A): 631 @ $8.91 | EDGAR |
| 2026-06-02 | 4 | MILANO VINCENT — Director | Grant/award (A): 1,122 @ $8.91 | EDGAR |
| 2026-05-19 | 4 | McKee Amy E — Director | Sale (S): 11,180 @ $8.97 | EDGAR |
| 2026-05-15 | 4 | Barnes Alane P — Chief Legal Officer | Option exercise (M): 62,500 @ $5.04 · Sale (S): 62,500 @ $9.54 · Option exercise (M): 62,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Menon Sandeep — Chief R&D Officer | Grant/award (A): 205,150 @ $0 · Grant/award (A): 441,350 (derivative) @ $0 | EDGAR |
| 2026-03-24 | 4 | HEGGIE THERESA — Director | Option exercise (M): 49,933 @ $6.30 · Sale (S): 49,933 @ $10.11 · Option exercise (M): 49,933 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Barnes Alane P — Chief Legal Officer | Option exercise (M): 150,000 @ $5.51 · Sale (S): 150,000 @ $9.15 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | McKee Amy E — Director | Grant/award (A): 642 @ $8.75 | EDGAR |
| 2026-03-03 | 4 | Milne Jill C. — Director | Grant/award (A): 528 @ $8.75 | EDGAR |
| 2026-03-03 | 4 | Frank Steven — Director | Grant/award (A): 1,285 @ $8.75 | EDGAR |
| 2026-03-03 | 4 | Stonehouse Jon P — Director | Grant/award (A): 421 @ $8.75 · Option exercise (M): 305,995 @ $3.22 · Disposition to issuer (D): 305,995 @ $8.64 · Option exercise (M): 305,995 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | MILANO VINCENT — Director | Grant/award (A): 848 @ $8.75 | EDGAR |
| 2026-01-27 | 4 | Milne Jill C. — Director | Grant/award (A): 2,582 · Grant/award (A): 12,272 @ $0 · Grant/award (A): 26,684 (derivative) @ $0 | EDGAR |
| 2025-12-23 | 4 | Gayer Charles K — President and CCO | Tax withholding (F): 11,477 @ $7.41 · Option exercise (M): 14,142 @ $3.22 · Option exercise (M): 10,091 @ $5.04 · Option exercise (M): 50,000 @ $5.51 · Option exercise (M): 14,142 (derivative) @ $0 · Option exercise (M): 10,091 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-23 | 4 | Barnes Alane P — Chief Legal Officer | Tax withholding (F): 16,902 @ $7.41 · Sale (S): 21,773 @ $7.65 | EDGAR |
| 2025-12-23 | 4 | Stonehouse Jon P — Chief Executive Officer, Director | Tax withholding (F): 61,793 @ $7.41 | EDGAR |
| 2025-12-19 | 4 | Ghias Babar — Chief Financial Officer | Grant/award (A): 121,700 @ $0 · Grant/award (A): 355,050 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Gayer Charles K — President and CCO | Grant/award (A): 471,000 @ $0 · Grant/award (A): 986,950 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Barnes Alane P — Chief Legal Officer | Grant/award (A): 121,700 @ $0 · Grant/award (A): 255,050 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Stonehouse Jon P — Chief Executive Officer, Director | Gift (G): 20,000 @ $0 · Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 | EDGAR |
| 2025-12-16 | 4 | Gayer Charles K — President and CCO | Tax withholding (F): 8,181 @ $7.57 | EDGAR |
| 2025-12-16 | 4 | Barnes Alane P — Chief Legal Officer | Tax withholding (F): 8,540 @ $7.57 · Sale (S): 21,210 @ $7.65 | EDGAR |
| 2025-12-16 | 4 | Stonehouse Jon P — Chief Executive Officer, Director | Tax withholding (F): 27,368 @ $7.57 | EDGAR |
| 2025-12-03 | 4 | Barnes Alane P — Chief Legal Officer | Option exercise (M): 91,004 @ $3.22 · Sale (S): 91,004 @ $7.10 · Sale (S): 50,906 @ $7.21 · Sale (S): 19,770 @ $7.65 · Option exercise (M): 91,004 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | McKee Amy E — Director | Grant/award (A): 783 @ $7.18 | EDGAR |
| 2025-12-02 | 4 | Frank Steven — Director | Grant/award (A): 1,566 @ $7.18 | EDGAR |
| 2025-12-02 | 4 | MILANO VINCENT — Director | Grant/award (A): 783 @ $7.18 | EDGAR |
| 2025-11-17 | 4 | SANDERS MACHELLE — Director | Sale (S): 9,600 @ $7.14 | EDGAR |
| 2025-09-03 | 4 | McKee Amy E — Director | Grant/award (A): 676 @ $8.31 | EDGAR |
| 2025-09-03 | 4 | Frank Steven — Director | Grant/award (A): 1,353 @ $8.31 | EDGAR |
| 2025-09-03 | 4 | MILANO VINCENT — Director | Grant/award (A): 676 @ $8.31 | EDGAR |
| 2025-08-15 | 4 | HEGGIE THERESA — Director | Option exercise (M): 30,000 @ $2.91 · Option exercise (M): 40,000 @ $5.41 · Sale (S): 70,000 @ $8.51 · Option exercise (M): 30,000 (derivative) @ $0 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-07-28 | 4 | Ghias Babar — CFO & Head of Corp Development | Grant/award (A): 147,000 @ $0 · Grant/award (A): 305,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | McKee Amy E — Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | HEGGIE THERESA — Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | SANDERS MACHELLE — Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Frank Steven — Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Galson Steven K — Director | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
Recent 8-K events — BIOCRYST PHARMACEUTICALS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-04 | 8-K/A | ? | EDGAR |
| 2026-06-29 | 8-K | ? 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BCRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →